跳到正文
原文
Medical Xpress·· 2026-10-21AI 评分54

研发阿尔茨海默病药物时意外发现血液中天然存在肽HAEE,或可作生物标志物

Search for Alzheimer's drug unexpectedly finds possible biomarker

AI 导读

研究团队为干扰Aβ斑块形成设计了四肽HAEE,在小鼠中获得初步结果,并意外发现人体血液中已天然存在同一肽段。HAEE水平与疾病状态相关,而阿尔茨海默病患者与健康人的Aβ水平相同;作者认为HAEE缺乏可能是阿尔茨海默病的原因之一,其血浓度或有助于诊断。研究发表于PNAS Nexus。

正文
Search for Alzheimer's drug unexpectedly finds possible biomarker
Distribution of the peptide HAEE in patients clinically diagnosed with Alzheimer's disease, stratified by the stage of the disease activity, and a group of healthy volunteers. Credit: Kopylov et al.

Researchers developed a drug for Alzheimer's disease and then discovered that the molecule already exists in human blood and is found at lower levels in cognitively impaired people. Now the authors are exploring the peptide as a biomarker as well as a treatment.

Sergey A. Kozin and colleagues designed a peptide to interfere with the growth of amyloid-β peptide (Aβ) plaques in the brain. Preventing the formation of such plaques has been proposed as a way to prevent Alzheimer's disease or treat it in its earlier stages, in part because Aβ plaque formation is believed to precede and potentially cause the spread of toxic tau protein.

The research is published in PNAS Nexus.

Specifically, the authors sought to disrupt abnormal interactions between Aβ and zinc ions, which are thought to be key to the plaque formation process. The tetrapeptide Ac-His-Ala-Glu-Glu-NH₂ (HAEE) blocks the primary zinc-binding center in Aβ monomers.

In the process of testing HAEE's suitability as a drug, the authors not only obtained promising results in mice but unexpectedly discovered that an identical peptide was already circulating in human blood. In effect, the authors had reverse-engineered a molecule that evolution had already produced. Furthermore, levels of HAEE correlate with disease status, while Aβ levels are the same in people with Alzheimer's disease and healthy people.

According to the authors, HAEE deficiency may be a cause of Alzheimer's disease, and HAEE blood concentration may be a useful biomarker to help diagnose the disease.

Publication details

Beyond Alzheimer's story: How an engineered molecule gained an endogenous essence, PNAS Nexus (2026).
academic.oup.com/pnasnexus/art … 93/pnasnexus/pgag320

Journal information: PNAS Nexus

Key medical concepts

Alzheimer's Disease

Who's behind this story?

Swati Mestri

Swati Mestri

Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Search for Alzheimer's drug unexpectedly finds possible biomarker (2026, October 20) retrieved 20 October 2026 from https://medicalxpress.com/news/2026-10-alzheimer-drug-unexpectedly-biomarker.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com